Physician profile
Todd A Taylor
NPI 1619911765
$3,170.13
in general payments reported to CMS, 2019-2025
32 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $75.72 · 2021: $362 · 2022: $493 · 2023: $543 · 2024: $252 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $585.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $407.45 | 2021-2025 | Linzess, Vraylar, Viberzi |
| Glaxosmithkline, LLC. | $305.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $249.50 | 2019-2024 | Breztri, Airsupra |
| Pfizer INC. | $185.43 | 2019-2024 | |
| Astellas Pharma US INC | $140.15 | 2021-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $137.98 | 2019-2023 | Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.21 | 2020-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Dexcom, INC. | $121.54 | 2023-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $100.94 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $90.05 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $76.48 | 2019-2022 | |
| Allergan, INC. | $72.08 | 2019 | |
| Sumitomo Pharma America, INC. | $58.44 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $54.28 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $53.33 | 2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.57 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $42.67 | 2019-2022 | |
| Abbott Laboratories | $41.97 | 2022-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $36.85 | 2021-2023 | |
| Amgen INC. | $34.54 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $34.20 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.06 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.24 | 2023 | Rexulti |
| Ardelyx, INC. | $19.13 | 2025 | Ibsrela |
| Biogen, INC. | $16.62 | 2022 | |
| Organon LLC | $16.47 | 2023 | Nexplanon |
| Exact Sciences Corporation | $15.90 | 2023 | Cologuard Collection Kit |
| Celgene Corporation | $15.09 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.30 | 2019 | |
| Genentech USA, INC. | $11.16 | 2019 | |
| Daiichi Sankyo INC. | $10.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.